In fact, most recent studies analyzing Chk1-mediated sensitization to chemotherapy involved solid tumors or myeloid malignancies and used antimetabolites like hydroxyurea or gemcitabine (GEM) [17–19] with limited utility in the treatment of lymphoid tumors. The gene discussed is CHEK1; the disease is lymphoid neoplasm.